Literature DB >> 18784735

Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries.

P Ferrari1.   

Abstract

Insufficient awareness of hypertension guidelines by physicians may be an impediment to achieving adequate blood pressure (BP) control rates in clinical practice. We therefore conducted an open intervention survey among primary care physicians in 1596 centres from 16 countries in four different continents to prospectively assess what is the BP goal defined by physicians for individual patients and what are the reasons for not intensifying antihypertensive treatment when BP goals are not achieved. Enrolled patients (N=35,302) were either not treated to goal (N=22,887) or previously untreated (N=12,250). Baseline systolic and diastolic BP averaged 159/95+/-15/12 mm Hg. BP goals defined by physicians averaged 136+/-6 mm Hg for systolic and 86+/-5 mm Hg for diastolic BP. Patients' individual risk stratification determined BP goals. At last visit BP averaged 132/81+/-11/8 mm Hg and values of <or=140/90 were reached in 92% of untreated and 80% of previously uncontrolled treated hypertensives. The main reasons for not intensifying antihypertensive treatment when BP remained above goal were the assumption that the time after starting the new drug was too short to attain its full effect, the satisfaction with a clear improvement of BP or with a BP nearing the goal, and the acceptance of good self-measurements. In this open intervention program in primary care, a large proportion of patients achieved recommended BP goals. The belief that a clear improvement in BP is acceptable and that the full drug effect may take up to several weeks to be reached are frequent reasons for treatment inertia when goals are not achieved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784735     DOI: 10.1038/jhh.2008.117

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  20 in total

1.  Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.

Authors:  Nelson Wang; Abdul Salam; Ruth Webster; Asita de Silva; Rama Guggilla; Sandrine Stepien; Jayanthi Mysore; Laurent Billot; Stephen Jan; Pallab K Maulik; Nitish Naik; Vanessa Selak; Simon Thom; Dorairaj Prabhakaran; Anushka Patel; Anthony Rodgers
Journal:  JAMA Cardiol       Date:  2020-11-01       Impact factor: 14.676

2.  One-Year Rates and Determinants of Poststroke Systolic Blood Pressure Control among Ghanaians.

Authors:  Fred Stephen Sarfo; Gloria Kyem; Bruce Ovbiagele; John Akassi; Osei Sarfo-Kantanka; Martin Agyei; Elizabeth Badu; Nathaniel Adusei Mensah
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-09-14       Impact factor: 2.136

3.  [Prevention of therapeutic inertia in the treatment of arterial hypertension by using a program of home blood pressure monitoring].

Authors:  Emilio Márquez Contreras; José Luis Martín de Pablos; Jacinto Espinosa García; José Joaquín Casado Martínez; Eugenio Sanchez López; José Escribano
Journal:  Aten Primaria       Date:  2011-10-20       Impact factor: 1.137

4.  Understanding racial disparities in treatment intensification for hypertension management.

Authors:  Meredith Manze; Adam J Rose; Michelle B Orner; Dan R Berlowitz; Nancy R Kressin
Journal:  J Gen Intern Med       Date:  2010-04-13       Impact factor: 5.128

5.  Is there a predictive profile for clinical inertia in hypertensive patients? An observational, cross-sectional, multicentre study.

Authors:  Vicente Gil-Guillén; Domingo Orozco-Beltrán; Emilio Márquez-Contreras; Ramón Durazo-Arvizu; Richard Cooper; Salvador Pita-Fernández; Diego González-Segura; Concepción Carratalá-Munuera; José Luis Martín de Pablo; Vicente Pallarés; Salvador Pertusa-Martínez; Antonio Fernández; Josep Redón
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 6.  Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

7.  Assessment of drug-related problems and their impact on blood pressure control in patients with hypertension.

Authors:  Rana Abu Farha; Iman Basheti; Hassan Abu Al Ruz; Akram Alsaleh; Salah AbuRuz
Journal:  Eur J Hosp Pharm       Date:  2015-10-16

8.  São Paulo call to action for the prevention and control of high blood pressure: 2020.

Authors:  Norm R C Campbell; Aletta E Schutte; Cherian V Varghese; Pedro Ordunez; Xin-Hua Zhang; Taskeen Khan; James E Sharman; Paul K Whelton; Gianfranco Parati; Michael A Weber; Marcelo Orías; Marc G Jaffe; Andrew E Moran; Frida Liane Plavnik; Venkata S Ram; Michael Brainin; Mayowa O Owolabi; Augstin J Ramirez; Eduardo Barbosa; Luiz Aparecido Bortolotto; Daniel T Lackland
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-11-25       Impact factor: 3.738

9.  Hypertension, knowledge, attitudes, and practices of primary care physicians in Ulaanbaatar, Mongolia.

Authors:  Maral Myanganbayar; Uurtsaikh Baatarsuren; Guanmin Chen; Roberta Bosurgi; Geoffrey So; Norm R C Campbell; Nasantogtokh Erdenebileg; Khulan Ganbaatar; Purevjargal Magsarjav; Manduukhai Batsukh; Tsatsralgerel Munkherdene; Tsolmon Unurjargal; Myagmartseren Dashtseren; Namkhaidorj Tserengombo; Batbold Batsukh; Andreas Bungert; Naranbaatar Dashdorj; Naranjargal Dashdorj
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-06-12       Impact factor: 3.738

10.  Longitudinal control of blood pressure among a cohort of Ghanaians with hypertension: A multicenter, hospital-based study.

Authors:  Fred S Sarfo; Linda Mobula; Jacob Plange-Rhule; Mulugeta Gebregziabher; Daniel Ansong; Osei Sarfo-Kantanka; Lynda Arthur; Jasper Sablah; Edith Gavor; Gilbert Burnham; David Ofori-Adjei
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-04-30       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.